Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Perivascular Epithelioid Cell Neoplasms × dactolisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroectodermal Tumors, Primitive 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Perivascular Epithelioid Cell Neoplasms 1 Neuroendocrine Tumors 1 Endometrial Neoplasms 1 Carcinoma, Transitional Cell 1 Breast Neoplasms 1 Angiomyolipoma 1

Interventions

elacestrant 1 dactolisib 1 Specimen Handling 1 RAD1901 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 CTLA-4 Antigen 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01690871 2013-08-02

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa

Novartis

Phase 2 Withdrawn

Tuberous Sclerosis, Angiomyolipoma, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡